Skip to main content
. 2020 Nov 11;3(3):311–317. doi: 10.1016/j.cjco.2020.11.003

Table 2.

Characteristics of patients with STEMI according to SARS-CoV-2 infection status

All (N = 116) SARS-CoV-2 (n = 17) Non-SARS-CoV-2 (n = 99) P
Age, years 66.3 ± 13.8 63.4 ± 13.2 66.8 ± 13.9 0.34
Male sex 79 (68) 12 (70) 67 (67) 0.81
Cardiac arrest at presentation 18 (15.5) 6 (35) 12 (12.1) 0.015
Time to revascularization 4 [2-48] 3 [2-48] 4 [2.1-48] 0.77
Nonobstructive coronary arteries 5 (4.3) 4 (23.5) 1 (1.1) < 0.001
Infarct-related artery 0.76
 Left main 1 (0.9) 0 (0) 1 (1.1)
 Left anterior descending 43 (38.7) 5 (38.4) 38 (38.8)
 Left circumflex 23 (20.7) 4(30.8) 19 (19.4)
 Right coronary artery 44 (39.6) 4 (30.8) 40 (40.8)
Type of culprit lesion 0.08
 Acute occlusion 80 (72) 12 (92) 68 (69.4)
 Stenosis > 50% 31 (27.9) 1 (7.7) 30 (30.6)
Coronary anatomy 0.037
 Single-vessel disease 47 (42) 9 (69.2) 38 (38.8)
 Multivessel disease 64 (57.6) 4 (30.7) 60 (61.2)
Procedural aspects
 Thromboaspiration 18 (16.2) 3 (23.1) 15 (15.3) 0.48
 Stent PCI 94 (84.6) 10 (76.9) 84 (85.4) 0.41
 Any PCI (balloon or stent) 97 (87.4) 11 (84.6) 86 (87.8) 0.75
 Anti-GP IIb/IIIa use 12 (10.8) 3 (23.1) 9 (9.2) 0.13
 Persistent no-reflow 8 (7.2) 4 (30.8) 4 (4.1) 0.0004
Outcome (all STEMI patients)
 In hospital death 15 (12.9) 7 (41.2) 8 (8.1) 0.0001
 In-hospital cardiac arrest 16 (13.8) 9 (52.9) 7 (7.1) < 0.001
 Cardiogenic shock or heart failure 30 (25.8) 8 (47.1) 22 (22.2) 0.003
 Mechanical complications 4 (3.4) 1 (5.9) 3 (3) 0.56
 LVEF on discharge, % 47 ± 13 47 ± 12 47 ± 15 0.95
 Peak Hs troponin, ng/L 3225 [1086-6030] 1650 [686-3572] 3520 [1177-6608] 0.038
 C-reactive protein, mg/L 4 [2-23] 31 [3-128] 4 [2-8] 0.026

Data are presented as n (%), mean ± SD, or mean [25%-75% quartile]. Bold values represent P < 0.05.

GP, glycoprotein; Hs, high-sensitivity; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

P value is given for contingency tables.